{"id":"afuresertib","safety":{"commonSideEffects":[{"effect":"Diarrhoea","drugRate":"63.6%","placeboRate":"","totalAtRisk":11,"totalAffected":7,"trialsReporting":1},{"effect":"Fatigue","drugRate":"45.5%","placeboRate":"","totalAtRisk":11,"totalAffected":5,"trialsReporting":1},{"effect":"Cough","drugRate":"27.3%","placeboRate":"","totalAtRisk":11,"totalAffected":3,"trialsReporting":1},{"effect":"Neutropenia","drugRate":"18.2%","placeboRate":"","totalAtRisk":11,"totalAffected":2,"trialsReporting":1},{"effect":"Vomiting","drugRate":"18.2%","placeboRate":"","totalAtRisk":11,"totalAffected":2,"trialsReporting":1},{"effect":"Chest discomfort","drugRate":"18.2%","placeboRate":"","totalAtRisk":11,"totalAffected":2,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"18.2%","placeboRate":"","totalAtRisk":11,"totalAffected":2,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"18.2%","placeboRate":"","totalAtRisk":11,"totalAffected":2,"trialsReporting":1},{"effect":"Decreased appetite","drugRate":"18.2%","placeboRate":"","totalAtRisk":11,"totalAffected":2,"trialsReporting":1},{"effect":"Epistaxis","drugRate":"18.2%","placeboRate":"","totalAtRisk":11,"totalAffected":2,"trialsReporting":1},{"effect":"Nasal congestion","drugRate":"18.2%","placeboRate":"","totalAtRisk":11,"totalAffected":2,"trialsReporting":1},{"effect":"Pruritus","drugRate":"18.2%","placeboRate":"","totalAtRisk":11,"totalAffected":2,"trialsReporting":1},{"effect":"Anaemia","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Lymphopenia","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Palpitations","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Ear discomfort","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Abdominal discomfort","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Abdominal distension","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Gastrooesophageal reflux disease","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Large intestine polyp","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Nausea","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Oesophageal discomfort","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Oesophageal pain","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Tooth disorder","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Asthenia","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Oedema","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Oedema peripheral","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Peripheral swelling","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Chronic sinusitis","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Conjunctivitis","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Helicobacter infection","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Nasopharyngitis","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Respiratory tract infection","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Sinusitis","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Tooth infection","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Hyperglycaemia","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Foot deformity","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Muscle spasms","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Temporomandibular joint syndrome","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Ageusia","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Anosmia","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Dizziness","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Paraesthesia","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Micturition urgency","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Nephrolithiasis","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Dyspnoea","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Erythema","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Pruritus generalised","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Rash","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1},{"effect":"Skin ulcer","drugRate":"9.1%","placeboRate":"","totalAtRisk":11,"totalAffected":1,"trialsReporting":1}]},"_chembl":{"chemblId":"CHEMBL2219422","moleculeType":"Small molecule","molecularWeight":"427.33"},"_fixedAt":"2026-03-30T13:06:24.509625","_dailymed":null,"_scrapedAt":"2026-03-28T00:44:15.254Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:42:57.330299+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_fixedFields":["pubmed(41)"],"trialDetails":[{"nctId":"NCT05383482","phase":"PHASE1, PHASE2","title":"Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1","status":"COMPLETED","sponsor":"Laekna Limited","startDate":"2022-07-01","conditions":"Solid Tumor, NSCLC, Cervical Cancer","enrollment":22},{"nctId":"NCT04851613","phase":"PHASE3","title":"Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Laekna Limited","startDate":"2022-02-18","conditions":"Breast Cancer","enrollment":256},{"nctId":"NCT04374630","phase":"PHASE2","title":"Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian","status":"COMPLETED","sponsor":"Laekna Limited","startDate":"2020-06-09","conditions":"Platinum-resistant Ovarian Cancer","enrollment":150},{"nctId":"NCT05390710","phase":"PHASE1","title":"PhI to Solid Tumors and PhII to Locally Advanced or mTNBC","status":"COMPLETED","sponsor":"Laekna Limited","startDate":"2021-06-12","conditions":"Solid Tumor, TNBC - Triple-Negative Breast Cancer","enrollment":21},{"nctId":"NCT04060394","phase":"PHASE1, PHASE2","title":"Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC","status":"COMPLETED","sponsor":"Laekna Limited","startDate":"2019-09-13","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":49},{"nctId":"NCT05489744","phase":"PHASE1","title":"Human Mass Balance and Biotransformation Study of [14C]Afuresertib","status":"COMPLETED","sponsor":"Laekna Limited","startDate":"2022-08-06","conditions":"Healthy Volunteer","enrollment":6},{"nctId":"NCT02177682","phase":"PHASE1","title":"Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-08-13","conditions":"Neoplasms, Haematologic","enrollment":9},{"nctId":"NCT01531894","phase":"PHASE2","title":"Continuation Study of the Oral AKT Inhibitor GSK2110183","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-02-08","conditions":"Cancer","enrollment":11},{"nctId":"NCT01827644","phase":"PHASE1","title":"Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04-24","conditions":"Cancer","enrollment":36},{"nctId":"NCT02040480","phase":"PHASE1","title":"Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-05","conditions":"Cancer","enrollment":18},{"nctId":"NCT02240212","phase":"PHASE1","title":"Study of Afuresertib Combined With Paclitaxel in Gastric Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-10","conditions":"Cancer","enrollment":29},{"nctId":"NCT02380313","phase":"PHASE1","title":"Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2015-10","conditions":"Cancer","enrollment":""},{"nctId":"NCT02235740","phase":"PHASE1","title":"A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)","status":"TERMINATED","sponsor":"Novartis","startDate":"2014-11","conditions":"Cancer","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":41,"recentPublications":[{"date":"2026 Feb 6","pmid":"41651834","title":"Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial.","journal":"Nature communications"},{"date":"2025 Dec 19","pmid":"41399494","title":"Organoid platinum-resistance model identifies KRT17 as a biomarker of targeted therapy in ovarian cancer.","journal":"iScience"},{"date":"2026 Jan 19","pmid":"41376385","title":"Anti-tumour and associated metabolic effects of repurposed afuresertib and taxifolin for glioblastoma treatment.","journal":"The Analyst"},{"date":"2025 Nov","pmid":"41151301","title":"Inhibition of AKT or mTOR molecules mitigates obesity-associated metabolic disorders in Riz1(-/-) mice with obesity.","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"date":"2025","pmid":"40678068","title":"Analysis of immune cell infiltration in the tumor microenvironment of cervical cancer and its impact on immunotherapy.","journal":"Frontiers in oncology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AFURESERTIB","genericName":"AFURESERTIB","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":1,"trialStats":{"total":9,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:42:57.330299+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}